What is the official website of ICON plc ?

The official website of ICON plc is http://www.iconplc.com.

What is ICON plc's cybersecurity risk score?

ICON plc has an AI-generated cybersecurity risk score of 796 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has ICON plc experienced?

According to Rankiteo, ICON plc currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has ICON plc been affected by any supply chain cyber incidents ?

According to Rankiteo, ICON plc has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does ICON plc have SOC 2 Type 1 certification ?

According to Rankiteo, ICON plc is not certified under SOC 2 Type 1.

Does ICON plc have SOC 2 Type 2 certification ?

According to Rankiteo, ICON plc does not hold a SOC 2 Type 2 certification.

Does ICON plc comply with GDPR ?

According to Rankiteo, ICON plc is not listed as GDPR compliant.

Does ICON plc have PCI DSS certification ?

According to Rankiteo, ICON plc does not currently maintain PCI DSS compliance.

Does ICON plc comply with HIPAA ?

According to Rankiteo, ICON plc is not compliant with HIPAA regulations.

Does ICON plc have ISO 27001 certification ?

According to Rankiteo,ICON plc is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does ICON plc operate in ?

ICON plc operates primarily in the Biotechnology Research industry.

How many employees does ICON plc have ?

ICON plc employs approximately 34,531 people worldwide.

Does ICON plc own any subsidiaries ?

ICON plc presently has no subsidiaries across any sectors.

How many LinkedIn followers does ICON plc have ?

ICON plc's official LinkedIn profile has approximately 667,545 followers.

What is the NAICS classification code for ICON plc ?

ICON plc is classified under the NAICS code 541714, which corresponds to Research and Development in Biotechnology (except Nanobiotechnology).

Does ICON plc have a Crunchbase profile ?

No, ICON plc does not have a profile on Crunchbase.

Does ICON plc have a LinkedIn profile ?

Yes, ICON plc maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/icon-plc-2.

How many cybersecurity incidents has ICON plc experienced ?

As of July 20, 2026, Rankiteo reports that ICON plc has not experienced any cybersecurity incidents.

How many peer or competitor companies does ICON plc have ?

ICON plc has an estimated 4,724 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

ICON plc

Boost Score +25 with badge (5 left)

796

/1000

Fair

821

/1000

Good

ICON plc Vendor Cyber Rating & Cyber Score

iconplc.com

Add Your Compliance Badge

Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.

ICON plc A.I CyberSecurity Scoring

Scoring History

ICON plc

ICON plc CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

ICON plc Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for ICON plc

Incidents vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for ICON plc in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for ICON plc in 2026.

Incident Types ICON plc vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for ICON plc in 2026.

Incident History - ICON plc (X = Date, Y = Severity)

Loading…

SUBSIDIARY

ICON plc Subsidiaries

ICON plc

Biotechnology Research

Website: http://www.iconplc.com

Company Size: 10,000+ employees

ICON Strategic SolutionsPharmaceutical Manufacturing

DOCSPharmaceutical Manufacturing

ICON Government and Public Health SolutionsBiotechnology Research

Clinical Research Management, Inc. (ClinicalRM)Biotechnology Research

AccellacarePharmaceutical Manufacturing

ICON GeneesmiddelenonderzoekPharmaceutical Manufacturing

ICONクリニカルリサーチ合同会社リサーチサービス

Loading…

ICON plc Similar Companies

Syneos Health

cb syneoshealth.com

Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.

Thermo Fisher Scientific

thermofisher.com

About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

CSL

cb csl.com

CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra

Agilent Technologies

cb agilent.com

Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.

Eurofins

cb eurofins.com

Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.

The National Institutes of Health

cb nih.gov

NIH is the only agency of its kind. We impact the health of the country and the world through unique and innovative medical research. Did you know that NIH is the largest public funder of biomedical research in the world, investing more than $32 billion a year to enhance life, and reduce illness and disability? NIH funded research has led to breakthroughs and new treatments, helping people live longer, healthier lives, and building the research foundation that drives discovery. Whether you are graduating with a bachelor's degree, working on your doctoral degree, entering the workforce for the first time, or changing careers, NIH offers a place for you to start and plenty of room to grow your career. When you join us, you’re not just advancing your career — you’re driving the health of our country forward. Official LinkedIn Account of the NIH. Privacy policy: http://go.usa.gov/x9svN Comment policy: https://bit.ly/3G6xq94 Engagement ≠ endorsement

Roche

cb roche.com

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation

Avantor

cb avantorsciences.com

Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 14,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor.

Fortrea

fortrea.com

Fortrea (Nasdaq: FTRE) is a leading global clinical research organization (CRO) dedicated to providing innovative clinical development solutions to the life sciences industry. With over 30 years of clinical research experience, Fortrea has evolved from Covance and Labcorp into a pureplay CRO built for biotech, biopharma, medical device and diagnostic innovators. Fortrea collaborates with both emerging and established companies to deliver agile, fit-for-purpose full service (FSO), functional service (FSP) and hybrid solutions. Fortrea provides comprehensive Phase I-IV clinical trial management, clinical pharmacology, and consulting services, backed by deep experience in more than 20 therapeutic areas. Operating in approximately 100 countries, our diverse and talented team brings scientific rigor, operational excellence, and a strong investigator site network to every trial. By combining the best of our legacy experience with forward-thinking innovation, Fortrea brings predictability to clinical trial execution and helps transform aspirations into outcomes. Together, exceptional is possible. Learn more at Fortrea.com

Loading…

NEWS

ICON plc CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

March 18, 2026 08:19 PM

ICON PLC (ICLR) CFO lists RSU and stock option holdings in Form 3

ICON PLC Chief Financial Officer Nigel Bernard John Clerkin filed an initial ownership report showing his equity interests in the company.

Read Article

March 18, 2026 08:13 PM

ICON PLC (ICLR) director Stephen Cutler reports 79,278 shares and options

Director Stephen A. Cutler reports 79278 ICON PLC Ordinary Shares plus several fully vested stock options with exercise prices from $140.38...

Read Article

March 18, 2026 07:51 PM

ICON PLC (ICLR) director Linda Grais reports initial share and RSU holdings

ICON PLC director Linda Grais files Form 3, reporting 5271 ordinary shares and restricted share units for 1732 underlying shares,...

Read Article

March 18, 2026 07:46 PM

ICON PLC (ICLR) CAO discloses initial share and RSU holdings

ICON PLC's Chief Accounting Officer Emer Lyons reports 752 ordinary shares and multiple restricted share unit awards vesting from 2026 to...

Read Article

March 18, 2026 07:32 PM

Julie O’Neill (ICLR) details initial ICON PLC share and RSU holdings

ICON PLC director Julie O'Neill files Form 3, reporting 1732 Restricted Share Units and 2698 ordinary shares, with RSUs vesting after May 22...

Read Article

March 18, 2026 07:29 PM

ICON PLC (ICLR) director details shares, RSUs and option holdings

Director Eugene Pacelli McCague reports his ICON PLC stake, including 2920 Ordinary Shares, 1732 RSUs granted in 2025, and 3255 fully vested...

Read Article

March 18, 2026 07:23 PM

ICON PLC (ICLR) director Climax details options, RSUs and share stakes

ICON PLC director Dr. John Climax files a Form 3 detailing existing stock options, restricted share units, and direct and indirect ordinary...

Read Article

March 18, 2026 07:15 PM

ICON PLC (ICLR) director reports initial Form 3 equity holdings

ICON PLC director Ciaran Murray reports 20452 ordinary shares and 2677 restricted share units in his Form 3, detailing current holdings and...

Read Article

March 18, 2026 07:00 AM

ICON plc (ICLR) CEO details stock option and RSU holdings

ICON plc Chief Executive Officer and director Barry Edward Balfe reported his initial ownership of company equity awards.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-12484

SUMMARY

A vulnerability in keras-team/keras version 3.15.0 allows unsafe deserialization of attacker-controlled PyTorch pickle data through the public `keras.layers.TorchModuleWrapper.from_config` method. This method invokes `torch.load(..., weights_only=False)` without requiring an explicit unsafe opt-in, such as a `safe_mode=False` parameter. When called outside a `SafeModeScope(True)` context, the absence of an ambient safe mode state permits unsafe deserialization by default. This issue can lead to arbitrary code execution if untrusted Keras layer configurations are processed using this method. The vulnerability arises because the method does not enforce safe deserialization practices unless explicitly guarded by Keras safe mode.

Published

Date2026-07-19

Updated

Date2026-07-19

RISK INFORMATION (Score: 7.8)

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.0/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

1.8

REFERENCES

https://huntr.com/bounties/ab14df49-13b5-4442-b754-3189430bfa28

CVE-2026-64186

SUMMARY

In the Linux kernel, the following vulnerability has been resolved: iommu/amd: Remove latent out-of-bounds access in IOMMU debugfs In iommu_mmio_write() and iommu_capability_write(), the variables dbg_mmio_offset and dbg_cap_offset are declared as int. However, they are populated using kstrtou32_from_user(). If a user provides a sufficiently large value, it can become a negative integer. Prior to this patch, the AMD IOMMU debugfs implementation was already protected by different mechanisms. 1. #define OFS_IN_SZ 8 ensures the user string <= 8 bytes, so e.g. 0xffffffff isn't a valid input. if (cnt > OFS_IN_SZ) return -EINVAL; 2. Implicit type promotion in iommu_mmio_write(), dbg_mmio_offset is int and iommu->mmio_phys_end is u64 if (dbg_mmio_offset > iommu->mmio_phys_end - sizeof(u64)) return -EINVAL; 3. The show handlers would currently catch the negative number and refuse to perform the read. Replace kstrtou32_from_user() with kstrtos32_from_user() to parse the input, and check for negative values to explicitly prevent out-of-bounds memory accesses directly in iommu_mmio_write() and iommu_capability_write().

Published

Date2026-07-19

Updated

Date2026-07-19

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-64185

SUMMARY

In the Linux kernel, the following vulnerability has been resolved: sysfs: don't remove existing directory on update failure When sysfs_update_group() is called for a named group and create_files() fails (e.g. -ENOMEM), internal_create_group() calls kernfs_remove(kn) on the group directory. In the update path, kn was obtained via kernfs_find_and_get() and refers to a directory that already existed before this call. Removing it silently destroys a sysfs group that the caller did not create. Only remove the directory if we created it ourselves. On update failure the directory remains as it is left empty by remove_files() inside create_files(), but can be repopulated by a retry.

Published

Date2026-07-19

Updated

Date2026-07-19

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-64184

SUMMARY

In the Linux kernel, the following vulnerability has been resolved: mm/damon/sysfs-schemes: call missing mem_cgroup_iter_break() damon_sysfs_memcg_path_to_id() breaks mem_cgroup_iter() loop without calling mem_cgroup_iter_break(). This leaks the cgroup reference. Fix the issue by calling mem_cgroup_iter_break() before the break. The issue was discovered [1] by Sashiko.

Published

Date2026-07-19

Updated

Date2026-07-19

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-64183

SUMMARY

In the Linux kernel, the following vulnerability has been resolved: efi: Allocate runtime workqueue before ACPI init Since commit 5894cf571e14 ("acpi/prmt: Use EFI runtime sandbox to invoke PRM handlers") ACPI PRM calls are delegated to a workqueue which runs in a kernel thread, making it easier to detect and mitigate faulting memory accesses performed by the firmware. Rafael reports that such PRM accesses may occur before efisubsys_init() executes, which is where the workqueue is allocated, leading to NULL pointer dereferences. Since acpi_init() [which triggers the early PRM accesses] executes as a subsys_initcall() as well, and has its own dependencies that may be sensitive to initcall ordering, deferring acpi_init() is not an option. So instead, split off the workqueue allocation into its own postcore initcall, as this is the only missing piece to allow EFI runtime calls to be made. This ensures that EFI runtime call (including PRM calls) are accessible to all code running at subsys_initcall() level.

Published

Date2026-07-19

Updated

Date2026-07-19

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…